$PRTA

Kingston Anne Evans sold $65K of PRTA

Kingston Anne Evans (Chief Strategy Officer) sold 7,662 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.47 on 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kingston Anne Evans
Published Jul 31, 2026, 12:31 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRTA
Neutral
medium confidence
Mentioned
$PRTA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRTANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan, which generally limits bearish inference.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

The article does not provide context on total insider holdings, tax/vesting needs, or whether other insiders sold or bought around the same time.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-30 after the 2026-07-29 sale date

Background

The article is a SEC Form 4 insider transaction disclosure for Prothena Corp Public Ltd Co (PRTA).

Company-level read

Ticker impact

$PRTANeutralMedium confidence
Context

Prothena disclosed an insider open-market sale by Chief Strategy Officer Kingston Anne Evans of 7,662 shares at $8.4729 on 2026-07-29.

Expected impact

Likely minimal, unless traders overinterpret insider selling as bearish.

Evidence & confidence

The filing specifies an open-market sale and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales under a 10b5-1 plan can be purely liquidity-driven and may not reflect a change in company outlook.

Key entities

  • PROTHENA CORP PUBLIC LTD CO

    Subject of the Form 4 insider transaction disclosure.

  • Kingston Anne Evans

    Chief Strategy Officer who sold 7,662 shares in an open-market transaction.

Related articles

$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

$PRTAMed

PROTHENA CORP PUBLIC LTD CO (PRTA): Results of Operations and Financial Condition

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provide